Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts

Clinical Breast Cancer

Volumn 3, Issue 3, 2002, Pages 196-200

  Harbeck, Nadia ^a   Schmitt, Manfred ^a   Kates, Ronald E ^a   Kiechle, Marion ^a   Zemzoum, Iris ^a   Jänicke, Fritz ^b   Thomssen, Chritoph ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Adjuvant therapy; Metastasis; Node negative breast cancer; Prediction of therapy response; Prognosis; Risk group assessment

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE EXTRACT; TUMOR ANTIGEN; UROKINASE;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MEDICAL SOCIETY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; VALIDATION PROCESS;

EID: 0036695216     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.023     Document Type: Article

References (41)

1. Andreasen PA, Kjöller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72:1-22.
2. Schmitt M, Wilhelm OG, Reuning U, et al. The plasminogen activation system as a novel target for therapeutic strategies. Fibrinolysis 2000; 14:114-132.
3. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78:1434-1441.
4. Sweep CGJ, Fritsche HA, Gion M, et al. Some (quality control) considerations on development, validation and application of immuno(metric) tumour marker assays in clinical research. An EORTC-NCI working group report. Int J Biol Markers 2002. In press.
5. Duffy MJ, O'Grady P, Devaney D, et al. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Cancer 1988; 62:531-533.
6. Grebenschikov N, Sweep F, Geurts A, et al. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int J Cancer 1999; 81:598-606.
7. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thrombosis Haemostasis 1997; 78:285-296.
8. Jänicke F, Schmitt M, Ulm K, et al. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 2:1049.
9. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4:69-78.
10. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem Thromb Hemostasis 1991; 17:303-312.
11. Jänicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24:195-208.
12. Grøondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53:2513-2521.
13. Foekens JA, Schmitt M, van Putten WLJ, et al: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12:1648-1658.
14. Fernö M, Bendahl PO, Borg Å, et al. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996; 32a:793-801.
15. Eppenberger U, Kueng W, Schlaeppi JM, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16:3129-3136.
16. Kim SJ, Siba E, Kobayashi T, et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multi-center basis. Clin Cancer Res 1998; 4:177-182.
17. Kute TE, Grøondahl-Hansen J, Shao SM, et al. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998; 47:9-16.
18. Knoop A, Andreasen PA, Andersen JA, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77:932-940.
19. Bouchet C, Hacène K, Martin JP, et al. Dissemination index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17:3048-3057.
20. Foekens JA, Peters HA, Look MP, et al. Urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60:636-643.
21. Jänicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. J Natl Cancer Inst 2001; 93:913-920.
22. Konecny G, Untch M, Arboleda J, et al. HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7:2448-2457.
23. Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20:1000-1009.
24. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94:116-128.
25. Cufer T, Vrhovec I, Borstnar S. Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival. Int J Biol Markers 2002; 17:33-41.
26. Harbeck N, Thomssen C, Berger U, et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54:147-157.
27. Harbeck N, Dettmar P, Thomssen C, et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers. six-year median follow-up. Br J Cancer 1999; 80:419-426.
28. Harbeck N, Alt U, Krüger A, et al. Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7:2757-2764.
29. Harbeck N, Ross J, Yurdseven S, et al. HER-2/neu gene amplification determined by in-situ hybridization (FISH) allows risk group assessment in node-negative breast cancer. Int J Oncol 1999; 14:663-671.
30. 0 therapy trial. Breast Cancer Res Treat 2001; 69:213 (Abstract #19).
31. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n = 3424). Cancer Res 2002. In press.
32. Muehlenweg B, Sperl S, Magdolen V, et al. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumors. Exp Opin Biol Ther 2001; 1:683-691.
33. Jänicke F, Thomssen C, Pache L, et al. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M, Graeff H, Janicke F, eds. Prospects in Diagnosis and Treatment of Cancer. Netherlands: Elsevier Science; 1994:207-218.
34. Foekens JA, Look MP, Peters HA, et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87:751-756.
35. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88:1456-1466.
36. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer November 1-3, 2000. J Natl Cancer Inst 2001; 93:979-989.
37. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19:3817-3827.
38. McGuire W. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83:154-155.
39. Hayes D. Do we need better prognostic factors in node-negative breast cancer? Arbiter. Eur J Cancer 2000; 36:302-306.
40. Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Med 1995; 1:1035-1039.
41. Wilex starts phase I trial with anti-metastatic urokinase inhibitor drug [press release]. 2001; Available at: http://www.wilex.de/frames/News/press.htm. Accessed August 7, 2002.